Medicare reimbursement for intra-spinal therapeutics administered in the physician office setting was recently greatly reduced by CMS’ regional MACs.

This reimbursement reduction for “J3010,” hydromorphone, may make it difficult for many physicians’ pain practices to continue to provide this pharmaceutical to their patients in this convenient, comfortable, and cost-effective office setting.

Sharing your experience will help illustrate the effect CMS’ reduction in reimbursement has on your ability to provide this therapy to patients in the office setting. Please describe the impact on your practice and patients in an email to stoppain@hartleymedical.com. To protect your patients’ privacy, do not include identifying details or names. I will follow up with you or your office staff to gain permission to post the consequences of this action.